Top Markets
#1 Pleasing Gold Pleasing Gold +1,432.33%
#2 PulseChain PulseChain +58.12%
#3 Merlin's Seal BTC Merlin's Seal BTC +32.98%
#4 BOOK OF MEME BOOK OF MEME +27.38%
#5 Ontology Gas Ontology Gas +26.35%
#6 Pump.fun Pump.fun +24.18%
#7 Unit Pump Unit Pump +24.18%
#8 Nockchain Nockchain +22.55%
#9 Neiro Neiro +20.80%
#10 SkyAI SkyAI +19.67%
Coin of the day
Pleasing Gold Pleasing Gold
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Classifica tra le azioni #26675
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Prezzo delle azioni
$5.54
Ultima sincronizzazione: 2024-09-18
Capitalizzazione di mercato
$38.76M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Alimera Sciences, Inc. (ALIM)

Categoria

Healthcare
Ricavi di Alimera Sciences, Inc. (ALIM)
Ricavi nel Jun 2024 TTM: $99.68M
Secondo gli ultimi rapporti finanziari di Alimera Sciences, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $99.68M. Nel 2022, l'azienda ha registrato ricavi di $54.13M una diminuzione rispetto a i ricavi dell'anno 2021, che erano pari a $59.03M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Alimera Sciences, Inc. da 2006 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $99.68M 23.44%
2023 $80.75M 49.19%
2022 $54.13M -8.30%
2021 $59.03M 16.15%
2020 $50.82M -5.79%
2019 $53.94M 14.85%
2018 $46.97M 30.79%
2017 $35.91M 4.60%
2016 $34.33M 53.01%
2015 $22.44M 166.39%
2014 $8.42M 349.95%
2013 $1.87M 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B 6,532.81%
IN